History, physical examination, height and weight 2. ECOG Performance Status 3. AE Assessment 4. Medications 5. CBC with differential, platelet count 6. Liver Functions and blood chemistries: Na, K, Cl, CO2, Ca, Mg, PO4, Creatinine, total bilirubin, direct bilirubin, alkaline phosphatase, AST, ALT, LDH 7. Beta-2 Microglobulin, CRP 8. TSH, Free T4, Free T3 9. Evaluation of creatinine clearance 10. Laboratory Disease Evaluation:  Quantitative serum immunoglobulin levels.  Serum protein electrophoresis (SPEP).  24-hour urine collection to determine creatinine clearance and protein excretion, urine electrophoresis (UPEP) required for participants with +UPEP at baseline. Otherwise, random UPEP is permitted. If the random UPEP is positive, a 24-hour urine collection is required.  Immunofixation of urine and serum protein regardless of SPEP and UPEP results. 11. Vital Signs (including ambulatory O2 sat) per Section 11 12. Bone marrow and aspirate as per Section 11 13. Skeletal bone survey to include cranium, axial skeleton and proximal long bones or alternative imaging to capture areas of bone disease at months 1 and 6 14. Study tubes as per Section 10 5.11.2 Progression Free Survival (+/- 14 days) Participants will be followed every 3 months for 5 years. Participants will be followed until time of disease progression, at which time they will be followed for survival as outlined 5.11.4. At the time of disease progression DF/HCC Protocol #: 18-280 Protocol Version Date: 10.17.2020 18 patients will have disease assessments and study bloods/aspirate as outlined in section 10. 1.